The Mylan Pharmaceuticals Epipen investigation follows weeks of media reports regarding the high price Mylan charges for the Epipen, and questions regarding the EpiPen packaging.
The Mylan EpiPen works by injecting a dose of the drug epinephrine into the user’s thigh to counter potentially dangerous allergic reactions to things like bee stings, shellfish and peanuts. Media reports contend that Mylan has a virtual monopoly on EpiPen sales as Mylan traditionally controls more than 90% of the Epipen market.
As has been widely reported, the price of the Mylan Epipen has rocketed from less than $100 in 2007, to more than $600 today. News reports also note that Mylan has taken other actions that have added significantly to the cost of having potentially lifesaving epinepherin injections for those that need it. In 2011, Mylan began selling its EpiPen exclusively in packs of two, meaning consumers no longer had the option of purchasing a single Epipen. Mylan has also recently reduced the expiration period for its EpiPens from two years to one year. Cutting the expiration date in half essentially requires consumers to purchase EpiPens twice as often as those same consumers had to before the expiration date change.
Raising the Epipen price, selling the Epipen in two-packs, and cutting the expiration period in half each have a profound impact in the cost of providing the life-saving Epipen to those that need it. Combined, these sales practices make the Epipen cost prohibitive and too expensive for many consumers.
If you purchased a two pack of a Mylan EpiPen and are interested in discussing what legal rights you may have, we would like to speak with you and explain the legal steps a consumer can take. Please contact Brian Penny by email at [email protected] or by telephone at (484) 342-0700. You are also invited to visit our website at www.lawgsp.com
